The European Medicines Agency's (EMA) Paediatric Committee (PDCO) released meeting minutes on April 13, 2026, detailing discussions on paediatric investigation plans (PIPs) and waivers for pharmaceutical products. The minutes outline the committee's decisions on several drug development programmes, impacting pharmaceutical companies seeking paediatric indications for new medicines.
The PDCO, a scientific committee within EMA, is responsible for assessing PIPs required under the Paediatric Regulation (EC) No 1901/2006. The regulation mandates that companies submit a PIP for any new medicine unless a waiver is granted, aiming to ensure that medicines for children are researched and developed appropriately.
Document Type and Status The meeting minutes are a procedural record of the committee's deliberations and decisions. They are not legally binding but provide transparency on regulatory reasoning. The minutes include details on PIP modifications, deferrals, and waivers, reflecting the committee's role in balancing the need for paediatric data with the practical challenges of conducting trials in children.
Policy Orientations and Trade-offs The discussions reveal a cleavage between accelerating paediatric drug development and managing the administrative burden on companies. The PDCO granted several waivers for conditions that do not affect children, reducing unnecessary trials. Conversely, it required additional data for certain products, extending timelines but potentially improving paediatric safety and efficacy. This trade-off impacts the speed of market access versus the depth of paediatric evidence.
Impact on Stakeholders - Pharmaceutical companies: Must comply with PDCO decisions, which can delay marketing authorisation if a PIP is required. Waivers reduce costs and time, while modifications may require additional investment in paediatric studies. - Children and paediatric patients: Benefit from better-researched medicines, but may face delayed access to new treatments if PIPs extend development timelines. - EMA and national competent authorities: Use the minutes to ensure consistent application of paediatric requirements across the EU, supporting regulatory harmonisation. - Academic researchers: May be affected by PIP requirements that prioritise industry-led studies over investigator-initiated research.
Expected Institutional Follow-up The PDCO will continue to review PIP submissions and waivers in upcoming meetings. The minutes will inform future guidance on paediatric development, potentially influencing revisions to the Paediatric Regulation. EMA may also use the discussions to update its training modules, following the April 7, 2026 release of a new module for the Clinical Trial Information System (CTIS).
← Atlas › News › Health & Lifestyle